1AI — Algorae Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- AU$18.56m
- AU$16.24m
- AU$0.14m
- 44
- 10
- 47
- 24
Annual income statement for Algorae Pharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.268 | 0.003 | 0.042 | 0.125 | 0.141 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2.28 | 2.39 | 2.13 | 2.2 | 1.7 |
| Operating Profit | -2.01 | -2.38 | -2.09 | -2.08 | -1.56 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -1.91 | -2.37 | -2.11 | -2.1 | -1.54 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.46 | -1.96 | -2.11 | -2.1 | -0.803 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.46 | -1.96 | -2.11 | -2.1 | -0.803 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.46 | -1.96 | -2.11 | -2.1 | -0.803 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.002 | -0.002 | -0.002 | -0.001 | -0 |